Open AccessPrimary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial
Author(s) -
Simone N. Koole,
Ruby M. van Stein,
Karolina Sikorska,
Desmond P.J. Barton,
Lewis Perrin,
Donal J. Brennan,
Oliver Zivanovic,
Berit Jul Mosgaard,
Anna Fagotti,
PierreEmmanuel Colombo,
Gabe S. Sonke,
Willemien J. van Driel
Publication year - 2020
Publication title -
international journal of gynecological cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.901
H-Index - 87
eISSN - 1525-1438
pISSN - 1048-891X
DOI - 10.1136/ijgc-2020-001231
Subject(s) - medicine , hyperthermic intraperitoneal chemotherapy , ovarian cancer , clinical endpoint , stage (stratigraphy) , oncology , cytoreductive surgery , surgery , cancer , randomized controlled trial , paleontology , biology
The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery improves recurrence-free and overall survival in patients with FIGO stage III ovarian cancer who are ineligible for primary cytoreductive surgery. The effect of HIPEC remains undetermined in patients who are candidates for primary cytoreductive surgery.